Penny Stocks Formula Review - The Best Penny Stock ( CTIC, SNSS, HUSA, GFA )

Los Angelas, CA -- (SBWIRE) -- 09/12/2012 -- Cell Therapeutics (NCM:CTIC) is very active today and traded between $2.89 - 3.68 with total traded volume of 12886405 shares. At a current price of 3.56, CTIC is +0.99 - +38.52% from the previous close of $2.57. Moreover, At Current Market Price, CTIC is in distance of +56.81% from its 50-day Moving Average price of $2.2703 and -16.83% from its 200-day Moving Average price of $4.2805. Cell Therapeutics Inc. shares climbed Tuesday after the company said it will start marketing its lymphoma drug Pixuvri in Europe in September. The company plans to first roll out the drug in Sweden, Denmark, and Finland in September. Austria and Norway will follow in early October. Product launches in Germany, the United Kingdom, and the Netherlands are planned for November. Pixuvri will be introduced to other European countries in 2013. However, as ardent observers of the market, we insist investors look past the daily market noise when making any investment decision. The safest way to make sure you don't get sideswiped by the market's crazy spikes is to look beyond the day-to-day movements and focus on what you can really understand -- a company's long-term prospects.

What’s Going With CTIC? Find Out Here:

Sunesis Pharmaceu (NCM:SNSS) is +0.85 - +32.20% from the previous close of $2.64. It traded between $3.43 - 4.02 with total traded volume of 8859315 shares. Keep a close eye on SNSS, as the stock has been showing unusual moves over the past weeks. At Current market price, SNSS has recovered +245.54% from its 52-week Low of 1.01 and has Pulled back -13.18% from its 52-week high of 4.02. Shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shoot the moon on the news that it’s increasing the size of its Phase 3 trial for its Vosaroxin leukemia drug by 225 patients to 675. This accomplishment is subsequent to a recommendation by the study’s independent Data & Safety Monitoring Board following its interim analysis of trial data. In turn, the recommendation triggers an obligation of Royalty Pharma to stake $25 million in Sunesis. The firm keeps a Buy rating and raises its price target to $8 on the stock.

Find out EXACTLY where SNSS is headed: Click Here

Houston American (AMEX:HUSA) is very active today and traded between $1.12 - 1.42 with total traded volume of 1201198 shares. At a current price of 1.42, HUSA is +0.32 - +29.09% from the previous close of $1.10. Moreover, At Current Market Price, HUSA is in distance of +48.19% from its 50-day Moving Average price of $0.9582 and -44.50% from its 200-day Moving Average price of $2.5585. Houston American Energy Corporation (AMEX:HUSA) shares are trading 16.36% higher today following on from yesterday’s 12% rise. The company has recently announced the commencement of drilling operations on its Zorro Gris #1 Well, situated in Colombia. The company’s shares recently traded as low as $1.12, dropping from around $7 one year ago. The well is expected to be drilled to a total measured depth of approximately 13,094 feet. Well results will be announced when available.

Should Investors Buy HUSA After The Recent Slump? Find Out Here

Gafisa SA Gafisa (NYSE:GFA)Brazilian stocks rose Tuesday following plans by the government to reduce electricity costs as it works to bolster economic growth. reported EPS of -2.054. For the Current Fiscal year, the company is expected to report EPS of -0.05. For the Next Quarter and Next Year, the company is expected to report EPS of 0.03 and 0.32 respectively. At Current Market Price, GFA is in distance of +30.45% from its 50-day Moving Average price of $3.3271 and +19.48% from its 200-day Moving Average price of $3.6323. shares of Gafisa GFA +12.14% surged 13%, their best performance in a month, after the home builder late Monday said it may spin off or sell part of its Alphaville Urbanismo SA property developments project.

Should Investors Buy HUSA After The Recent Slump? Find Out Here

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com